Andere Sprachen Novo Nordisk A/S

Aktien

A3EU6F

DK0062498333

NOVO B

Pharmazeutika

Realtime-Estimate Cboe Europe Andere Börsenplätze 16:19:27 13.12.2024			% 5 Tage	% 1. Jan.
757.95 ^DKK	-3.38%		-3.77%	+8.28%

16:14	DAX knapp unter Rekordhoch -Rally bei Munich Re	DJ
12:00	Novo Nordisk A/S beantragt eine Erweiterung des Labels in den USA	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Les actions en mouvement : Les réassureurs en pleine forme, Novo Nordisk baisse encore	14:16
UK's private obesity drug market chooses Lilly's Mounjaro over Wegovy	13:59
Novo Nordisk A/S : European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease related events Form 6 K	12:07
Novo Nordisk A/S Files for A Label Expansion in the Us	12:00
Borse Europa, settimana in calo dopo lunga serie positiva	10:57
Broadcom s'intercale entre les baisses de taux	08:01
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market	07:04
Health Care Down on Growth Doubts -- Health Care Roundup	00:14
Evotec SE announces first projects for LAB eN-2 drug discovery accelerator with Novo Nordisk	12.12.
Novo Nordisk: l'Ozempic efficace contre les affections rénales	12.12.
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks	12.12.
Europe allows Novo to include reduction of kidney disease in Ozempic label	12.12.
Novo Nordisk's Diabetes Drug Ozempic Gets EU Panel's Backing for Label Expansion	12.12.
Novo Nordisk : avis positif de l'UE pour l'Ozempic	12.12.
Novo Nordisk Wins EU Regulator's Positive Opinion for Ozempic's Kidney Disease-related Label Update	12.12.
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events	12.12.
Novo Nordisk A/S Announces European Regulatory Authority Adopts Positive Opinion for an Update of the Ozempic®? Label to Reflect Risk Reduction of Kidney Disease-Related Events	12.12.
Evotec, Novo Nordisk Drug Discovery Accelerator Selects First Three Projects for Cardiometabolic Conditions	11.12.
Evotec SE Announces First Projects for LAB eN2 Drug Discovery Accelerator with Novo Nordisk	11.12.
Eikonizo Therapeutics, Inc. announced that it has received funding from Novo Nordisk A/S	10.12.
Novo Nordisk A/S : Share repurchase programme Form 6 K	09.12.
Novo Nordisk A/S - share repurchase programme	09.12.
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction	09.12.
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings	09.12.
Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide	09.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

NOVO NORDISK : Interessante Gleichungen entwickeln sich für Novo Nordisk

Am 06. Dezember 2024 um 13:20 Uhr

Novo Nordisk A/S: Anhaltende Volatilität

Am 07. November 2024 um 14:25 Uhr

Ausführlich: Novo Nordisk CEO über Ausblick, Wegovy, US-Markt

Am 07. August 2024 um 12:07 Uhr